Cargando…

Pembrolizumab-induced necrotizing myositis in a patient with metastatic non-small-cell lung cancer: a case report

A 57-year-old man presented with swelling and pain in the lower limbs, inability to walk and increasing dyspnea for 2 days. Because of refractory stage IV non-small-cell lung cancer, pembrolizumab was started 21 days before presentation. Since then, he experienced general discomfort, fatigue and bil...

Descripción completa

Detalles Bibliográficos
Autores principales:	Claus, Jonas, Van Den Bergh, Annelies, Verbeek, Sanne, Wauters, Els, Nackaerts, Kristiaan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6802710/ https://www.ncbi.nlm.nih.gov/pubmed/31645893 http://dx.doi.org/10.2217/lmt-2018-0017

Ejemplares similares

Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm
por: Haddox, C. L., et al.
Publicado: (2017)

RNA-sequencing in non-small cell lung cancer shows gene downregulation of therapeutic targets in tumor tissue compared to non-malignant lung tissue
por: Reynders, Kobe, et al.
Publicado: (2018)

Pembrolizumab‐induced myasthenia gravis with myositis in a patient with lung cancer
por: Hibino, Makoto, et al.
Publicado: (2018)

Postpartum Necrotizing Myositis of the Uterus
por: Faro, Sebastian
Publicado: (1997)

Necrotizing myositis – Case report
por: Lu, Pei-Hsuan, et al.
Publicado: (2020)

Early development of pembrolizumab‐induced fulminant myositis and cardiotoxicity in a patient with metastatic thymoma
por: Jang, Soo Yeon, et al.
Publicado: (2022)

Paraspinal muscle involvement in pembrolizumab-associated myositis
por: Nosaki, Yasunobu, et al.
Publicado: (2020)

Immunotherapy in non-metastatic non-small cell lung cancer: Can the benefits of stage IV therapy be translated into earlier stages?
por: Deslypere, Griet, et al.
Publicado: (2018)

Statin-Induced Necrotizing Autoimmune Myositis
por: Akivis, Yonatan, et al.
Publicado: (2022)

Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives
por: Somasundaram, Ashwin, et al.
Publicado: (2017)

Pure White Cell Aplasia and Necrotizing Myositis
por: Kim, Peter Geon, et al.
Publicado: (2016)

Perioperative management of immune-mediated necrotizing myositis
por: Montané-Muntané, Mar, et al.
Publicado: (2022)

Asymptomatic necrotizing myositis in a young male with progressive interstitial lung disease
por: Baah, Samantha, et al.
Publicado: (2021)

Pembrolizumab on pre-existing inclusion body myositis: a case report
por: Uchio, Naohiro, et al.
Publicado: (2020)

Statin-Induced Necrotizing Autoimmune Myositis: Diagnosis and Management
por: Cha, David, et al.
Publicado: (2021)

Necrotizing Cellulitis and Myositis in a Neutropenic Leukemic Patient
por: Alok, Akankcha, et al.
Publicado: (2021)

Immune-Mediated Necrotizing Myositis Presenting with Cutaneous Lesions
por: Souza, Bruno de Castro e, et al.
Publicado: (2021)

Emergence of Myasthenia Gravis with Myositis in a Patient Treated with Pembrolizumab for Thymic Cancer
por: Huh, So-Young, et al.
Publicado: (2018)

Pembrolizumab plus chemotherapy in Japanese patients with metastatic squamous non‐small‐cell lung cancer in KEYNOTE‐407
por: Sugawara, Shunichi, et al.
Publicado: (2023)

Necrotizing streptococcal myositis of the upper extremity: a case report
por: Reichert, Johannes C., et al.
Publicado: (2017)

Necrotizing Bacterial Myositis as the Initial Presentation of Severe Aplastic Anaemia
por: Rørvik, Synne Dragesund, et al.
Publicado: (2021)

Statin-Related Necrotizing Autoimmune Myositis: More Than Myalgia
por: Scheuing, William J, et al.
Publicado: (2022)

Statin-Induced Autoimmune Necrotizing Myositis: A Case Report
por: Almadhoun, Hussein, et al.
Publicado: (2022)

FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non‐Small Cell Lung Cancer: First‐Line Therapy and Beyond
por: Pai‐Scherf, Lee, et al.
Publicado: (2017)

Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA
por: Zeng, Xiaohui, et al.
Publicado: (2019)

First‐line pembrolizumab vs chemotherapy in metastatic non‐small‐cell lung cancer: KEYNOTE‐024 Japan subset
por: Satouchi, Miyako, et al.
Publicado: (2020)

Pembrolizumab plus pemetrexed‐platinum for metastatic nonsquamous non–small‐cell lung cancer: KEYNOTE‐189 Japan Study
por: Horinouchi, Hidehito, et al.
Publicado: (2021)

First‐line pembrolizumab vs chemotherapy in metastatic non‐small‐cell lung cancer: KEYNOTE‐024 Japan subset
por: Satouchi, Miyako, et al.
Publicado: (2021)

Arthritis and Myositis in a Patient Treated with Programmed Cell Death-1 (PD-1) Inhibitor Pembrolizumab for Lung Cancer
por: Pagkopoulou, Eleni, et al.
Publicado: (2020)

Pembrolizumab‐induced myasthenia gravis with myositis and presumable myocarditis in a patient with bladder cancer
por: Todo, Maki, et al.
Publicado: (2019)

Management of necrotizing myositis in a field hospital: a case report
por: Bharathi, Ramanathan Saranga, et al.
Publicado: (2009)

COVID-19 IgG-related autoimmune inflammatory necrotizing myositis
por: Veyseh, Maedeh, et al.
Publicado: (2021)

A Case of Suspected Statin-Related Delayed Onset Necrotizing Myositis
por: Smirlis, Elias, et al.
Publicado: (2022)

Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date
por: Vachhani, Pankit, et al.
Publicado: (2016)

Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial
por: Welsh, James, et al.
Publicado: (2020)

The reimbursement process in three national healthcare systems: variation in time to reimbursement of pembrolizumab for metastatic non-small cell lung cancer
por: Sharman Moser, Sarah, et al.
Publicado: (2023)

Pembrolizumab-Associated Stevens-Johnson Syndrome in a Patient With Metastatic Non-small Cell Lung Cancer: A Case Report
por: Sandhu, Michael, et al.
Publicado: (2023)

Atorvastatin-induced necrotizing autoimmune myositis: An emerging dominant entity in patients with autoimmune myositis presenting with a pure polymyositis phenotype
por: Troyanov, Yves, et al.
Publicado: (2017)

Pembrolizumab-induced myasthenia gravis-like disorder, ocular myositis, and hepatitis: a case report
por: Tian, Chia-Yi, et al.
Publicado: (2021)

Pembrolizumab-Induced Fatal Myasthenia, Myocarditis, and Myositis in a Patient with Metastatic Melanoma: Autopsy, Histological, and Immunohistochemical Findings—A Case Report and Literature Review
por: Giovannini, Elena, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_l3h2bcsqh9ljj164kdu3ffhtdn